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 ABSTRACT
Anderson -Fabry disease (AFd) is a rare disorder characterised by the deficiency or absence of lysosomal enzy-
matic­alpha­‑galactosidase­A­activity­(α­‑Gal­A)­that­leads­to­progressive­and­systemic­accumulation­of­glycosphin-
golipids. The clinical manifestations are variable but kidney disease usually manifests before the fourth decade 
of life and chronic renal failure rapidly progresses to end -stage renal disease (ESRD), requiring dialysis and kidney 
transplantation (KT). In patients with a definite diagnosis, enzyme replacement therapy (ERT) is recommended 
as soon as there are early clinical signs of kidney, heart or brain involvement. We present a case of a kidney 
transplant patient who was diagnosed with AFd nine years after KT, confirming the difficulty that may exist in an 
early diagnosis of this disease even among high -risk groups. At this stage, in addition to renal damage, the patient 
already had advanced disease and established organ injury, including ocular, pulmonary, cerebrovascular and 
cardiac. He started agalsidase beta (Fabrazyme®) intravenously every two weeks at a dose of 1 mg/kg body 
weight. During ten years of treatment no major adverse events were reported and our experience indicates that 
ERT is a safe and effective treatment for extra -renal Fabry manifestations in KT patients.
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 INTRODUCTION
Anderson -Fabry disease (AFd) is a rare X -linked reces-
sive metabolic disorder characterised by the deficiency 
or absence of lysosomal enzymatic alpha -galactosidase 
A­activity­(α­‑Gal­A).­The­enzyme­defect­leads­to­pro-
gressive accumulation of glycosphingolipids, particu-
larly globotriaosylceramide (GL -3; also abbreviated 
Gb3), in all kinds of cells1. The clinical manifestations 
are variable and range from the severe phenotype in 
males to an asymptomatic disease course occasionally 
observed in females, with a variety of clinical presenta-
tions in between. In the classic phenotype, the first 
clinical symptoms typically begin in childhood and ado-
lescence and are characterised by myalgia, arthralgia, 
acroparesthesia, fever, cutaneous angiokeratomas and 
corneal opacities. Later, severe renal impairment and 
involvement of the cerebrovascular and cardiovascular 
systems occur2.
The estimated incidence of AFd is 1 in 40,000 to 
100,000 live births, excluding the polymorphisms and 
mutations of uncertain significance1. Still the diagnosis 
may be delayed for many years or even missed, and 
this underestimates the true prevalence of the 
disease3.
Nephropathy in Fabry disease is characterised by 
GL -3 deposition in all glomerular cell types, particularly 
in podocytes; the results of Tøndel et al.4, using 
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ultrastructural morphologic studies on human kidney 
biopsies, suggests that podocyte foot process efface-
ment represents a very early sign of kidney injury in 
Fabry disease, preceding the onset of clinically overt 
urinary protein loss. As proteinuria is a strong predictor 
of progression to end -stage renal disease in Fabry dis-
ease, these early morphological findings in Fabry 
nephropathy are clinically significant. Later, deposition 
of glycosphingolipids in other kidney cells (tubular epi-
thelial cells, endothelial and vascular smooth muscle 
cells) leads to microvascular dysfunction, occlusion and 
ischaemia, with subsequent development of tubular 
atrophy, segmental and global sclerosis and interstitial 
fibrosis5,6. Proteinuria usually manifests before the 
fourth decade of life and chronic renal failure rapidly 
progresses to end -stage renal disease (ESRD) requiring 
dialysis and kidney transplantation (KT)7. Several 
reports show that KT can be safely proposed to Fabry 
patients5,8 -11 and, in spite of heart and cerebrovascular 
complications which may reduce long -term patient 
survival, KT should be recommended as a first choice 
in renal replacement therapy for ESRD patients7,10.
Enzyme replacement therapy (ERT) with either agal-
sidase alfa or agalsidase beta has been developed for 
AFd treatment, and was approved in 2001. In 2015, 
the European Fabry Working Group published a con-
sensus document with recommendations for initiation 
and cessation of ERT in patients with AFd12, where they 
stated that in patients with a definite diagnosis, ERT is 
recommended as soon as there are early clinical signs 
of kidney, heart or brain involvement. Also treatment 
should not be withheld from patients with severe renal 
insufficiency (GFR < 45 mL/min/1.73 m2).
Data on the use of ERT in patients with a functioning 
KT is scarce and, therefore, whether ERT is safe and 
effective in treating extra -renal manifestations in this 
population5,10 requires additional studies with a higher 
number of patients and a longer follow -up time.
We present a case of a KT patient with a functioning 
allograft and over 10 years of successful ERT. It also 
underlines the difficulty that may exist in an early diag-
nosis in this lysosomal storage disease.
 CASE REPORT
A 36 -year -old male patient was first referred for a 
pre -transplant consultation in our Nephrology depart-
ment in 1995.
In September 1994 he presented to the accident 
and emergency (A&E) department of his local hospital 
with severe hypertension (blood pressure 200/110 
mmHg) and renal dysfunction (serum creatinine 11.5 
mg/dL). He had sought no prior medical contact. Ultra-
sound scan showed small and hyperechoic kidneys. In 
spite of blood pressure control he progressed to renal 
failure and started maintenance haemodialysis by cen-
tral catheter on October 4th 1994.
The first pre -transplant consultation was held in 
December 1995. The patient had been on dialysis for 
about a year via arteriovenous fistula and without sig-
nificant complications. Blood pressure was controlled 
with an angiotensin -converting -enzyme inhibitor (enal-
april 10 mg once a day) and a dihydropyridine calcium 
channel blocker (nifedipine 20 mg twice a day). He still 
had residual diuresis of about 1000 mL/day. There was 
no family history of Fabry’s disease, although his broth-
er had advanced renal failure and had died one year 
earlier in another hospital. The post -mortem examina-
tion indicated ischaemic leukoencephalopathy as cause 
of death. The patient reported mild vision decrease 
and occasional acroparesthesias. He did not have angio-
keratomas or hypohidrosis. On physical examination 
the blood pressure was 120/74 mmHg and the heart 
rate was regular, at 70 beats/min. Cardiac auscultation 
revealed a systolic murmur at the left sternal border. 
Electrocardiography was unremarkable. Echocardio-
graphic evaluation assessed normal cardiac ejection 
fraction (80%) with mild dilatation of both the left 
atrium (40 mm, for a normal of 22 -38 mm) and of the 
left ventricular end -diastolic diameter (58 mm, for a 
normal of 34 -54 mm); the valves were normal. There 
was no history of previous transfusions. He was evalu-
ated by vascular surgery and urology and no contrain-
dication to kidney transplant was found.
Deceased renal transplant was performed on June 
22nd 1996. The recipient presented three HLA A, B, DR 
mismatches with the donor. The induction immunosup-
pressive agents were cyclosporine and methylpredniso-
lone. He had immediate diuresis. At discharge, he was 
immunosuppressed with prednisolone 25 mg/day, aza-
thioprine 50 mg/day and cyclosporine 2.8 mL twice a 
day. Blood pressure was controlled with nifedipine 20 
mg twice a day; his serum creatinine was 1.5 mg/mL 
and decreased to 1.0 mg/dL one month later.
After transplant, he continued evaluation at routine 
post -transplant assessments, maintaining good graft 
function. He developed progressive vision loss and was 
referred to an ophthalmology appointment. Five years 
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after renal transplantation, in 2001, he underwent 
cataract surgery and corneal deposits were observed 
at that time. He also developed respiratory symptoms 
(shortness of breath and wheezing) so he performed 
a lung function test (spirometry) which indicated a 
moderate obstructive airway limitation.
At this stage, taking the history of chronic kidney dis-
ease with hypertension and proteinuria, corneal opaci-
ties (cornea verticillata) and family medical history 
including early death of his brother who had as diagnosis 
at the time of death chronic kidney disease and ischaemic 
leukoencephalopathy, allowed the doctors who followed 
the patience to consider AFd as a diagnosis. In September 
2002 biochemical diagnosis of Fabry’s disease was made, 
using enzymatic activity measurement. The leukocyte-
-specific activity of alpha -galactosidase A was low at 0.8 
nmol/h/mg of protein (normal range: 36 -80 nmol/h/
mg). The genetic study identified a nonsense mutation 
(R220X) in the alpha -Gal A gene, associated with the 
classic phenotype of AFd. Family screening was per-
formed in another hospital. As mentioned earlier, the 
patient had one brother who died, and has two sisters 
as well. One sister has AFd and is under ERT. He also has 
a nephew (son of the affected sister) who was also diag-
nosed with AFd and treated in Geneva, Switzerland. In 
1994, this nonsense mutation (R220X) was reported for 
the first time13: it is predominantly renal and causes 
disease in both genders.
After diagnosis, during 2003 and 2004, the renal 
function was stable with serum creatinine around 1.4 
mg/dL, estimated glomerular filtration rate (eGFR) 
according to MDRD formula of 55 mL/min/1.73 m2, 
and no proteinuria was detected. Electrocardiography 
showed asymptomatic bradycardia (58 beats per min-
ute) and criteria for left ventricular hypertrophy. An 
echocardiographic study was also performed and 
revealed left ventricular hypertrophy with an interven-
tricular septum of 18 mm (N < 12) and a posterior wall 
thickness of 15 mm (N < 11). Brain magnetic resonance 
imaging (MRI) exhibited periventricular white -matter 
lesions and deep lacunar infarcts.
Enzyme replacement therapy was initiated on April 
2005, by injection of recombinant alpha -galactosidase 
(Fabrazyme – agalsidase beta) at 1 mg per kg body-
weight once every two weeks. The treatment infusions 
were well tolerated and the patient has now been under 
treatment for over 10 years.
During these 10 years of treatment, diagnosis of neu-
rosensory deafness was made and, in 2009, cochlear 
implants were implanted in the patient. Further, in 2014, 
asymptomatic bradycardia was detected (heart rate at 
rest 35 -38 beats per minute). Electrocardiography 
revealed prolongation of the PR interval, culminating 
in a non -conducted P wave, with 2:1 pattern, leading 
to the diagnosis of atrioventricular block 2nd degree, 
Mobitz I. After excluding the main causes of secondary 
aetiologies for atrioventricular block (beta -blockers, 
digoxin, amiodarone, inferior myocardial infarction, 
myocarditis), permanent pacing was placed.
Nineteen years after renal transplant and ten years 
after ERT initiation, the patient maintained serum cre-
atinine of 1.5 mg/dL, and eGFR (MDRD) of 48 mL/
min/1.73 m2. Proteinuria was stable at 0.35 g/g and 
minimum cyclosporine A level was 118 ng/mL. Renal 
ultrasonography showed graft with normal longitudinal 
size, normal parenchymal thickness and mild echo-
genicity increase. Lung function test showed a mixture 
of restrictive and obstructive airflow limitation, both 
mild. A two -dimensional Doppler echocardiographic 
study performed revealed left ventricular hypertrophy 
with an interventricular septum 19 mm (18 mm before 
ERT) and a posterior wall thickness of 17 mm (15 mm 
before ERT). A stress myocardial perfusion scan (phar-
macologic intervention) revealed normal function with 
left ventricular ejection fraction estimated of 56%. A 
brain MRI showed severe multifocal leukoencephalopa-
thy and lacunar ischaemic lesions located in the deep 
arterial territory (basal ganglia and the brainstem), 
similar to those previously observed.
 DISCUSSION
Anderson -Fabry disease results in kidney damage 
and leads to progressive impairment of renal function 
in almost all male patients and in a significant percent-
age of females14. According to the data of Schiffmann 
et al.15, patients with proteinuria of at least 1 g/day 
had a worse prognosis.
More­than­600­variants­in­the­α­‑galactosidase­A­gene­
have been described, generating considerable variabil-
ity in age at disease onset and in disease progression 
rate12. Patients with ESRD have been shown to have 
an increased prevalence of AFd and case -finding studies 
among this population16 -18 suggest a much higher 
prevalence than that reported in the general popula-
tion1. Some patients do not present with the typical 
and classical features of AFd and have a more limited 
renal phenotype, which may be difficult to recognise16, 
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particularly in the absence of previously identified fam-
ily members. This phenotype may be referred to as 
non -classical AFd or attenuated phenotypes. Patients 
with non -classical AFd may present one single non-
-specific symptom, such as chronic kidney disease or 
left ventricular hypertrophy (LVH)12. In 2009, an Aus-
trian study with 1306 patients from 30 kidney trans-
plant centres that uncovered two previously unrecog-
nised cases with AFd was published18. This study was 
the first to show that this diagnosis can be missed even 
in patients who undergo kidney transplantation. There-
fore, given the increased risk of adverse cardiovascular 
and cerebrovascular events in patients with AFd, the 
availability for treatment with ERT, and the diagnosis 
and genetic counselling that can be offered to them 
and their extended families, is a diagnosis that is worth 
considering and cannot be overlooked. The diagnostic 
confirmation relies on the demonstration of a deficient 
activity of alpha -galactosidase activity in plasma or 
leukocytes in males, whilst in heterozygous females, in 
whom alpha -galactosidase A activity is highly variable, 
genotyping is essential for a diagnosis. Genotyping can 
also be useful in male patients to assist with tracing 
family history of the disease1,12.
Kidney transplantation should be endorsed as a first 
choice in renal replacement therapy for patients suf-
fering from ESRD, since graft and patient survival are 
similar in patients without AFd, at three and five years 
post -transplant19,20. In 2009, a study examined 197 
kidney transplant recipients with AFd and showed that 
AFd patients had a 40% lower risk of returning to dialysis 
compared to both matched and unmatched cohorts of 
patients with other causes of ESRD, but had a higher 
risk of death (hazard ratio 2.15; 95% confidence interval 
1.52 -3.02) compared to a matched cohort of patients 
with other causes of ESRD11.
Agalsidase beta (Fabrazyme®) is a recombinant form 
of­human­α­‑Gal­A­used­for­ERT­in­Fabry­disease­and­is­
given intravenously every two weeks at a dose of 1 
mg/kg body weight. Agalsidase alfa (Replagal®) is also 
available in some countries for treatment of Fabry dis-
ease (0.2 mg/kg/2 weeks)12. Both seem to be safe and 
well tolerated in renal transplant patients, but this data 
needs to be confirmed by randomised controlled stud-
ies with an appropriate sample size8. One randomised 
open -label study21 compared the effect of agalsidase 
alfa with that of agalsidase beta, using the same dose 
of 0.2 mg/kg every other week in both treatment arms, 
on the primary endpoint, defined as a reduction in left 
ventricular mass (LVM) after 12 and 24 months. After 
12 and 24 months of treatment no reduction in LVM 
was observed in either treatment arm. A systematic 
review published in 200922 concluded that data avail-
able were more robust for enzyme replacement therapy 
in patients with AFd at 1 mg/kg compared with 0.2 mg/
kg every other week. Beneficial effects with either dose 
or preparation were variable. In this systematic review, 
the lack of reporting of the review process, unclear 
study quality, and the possibility of missing studies 
mean these conclusions should be viewed with 
caution.
Recently, Germain et al. reported a study evaluating 
the ten -year outcome of enzyme replacement therapy 
with agalsidase beta in patients with AFd23. The study 
enrolled 52 patients with median agalsidase beta treat-
ment duration of 10 years (25th -75th: 7.3 -10.3 years) 
and they evaluated the following outcomes: severe 
clinical events, renal function and cardiac structure. 
The study concluded that agalsidase beta is effective 
and safe, as most patients remained alive and event-
-free during follow -up time: 42/52 patients did not 
experience any severe clinical event during the treat-
ment interval and 49/52 patients were alive at the end 
of the study period. They also reported that patients 
who initiated treatment at a younger age and with less 
kidney involvement benefited the most from therapy. 
However, it is important to note that patients were 
excluded if their serum creatinine concentration 
exceeded­2.2­mg­per­decilitre­(194.5­μmol­per­litre),­if­
they were undergoing dialysis, or if they had undergone 
kidney transplantation24.
Limited data are available on the effects of ERT after 
kidney transplantation. Although kidney graft produces 
α­‑Gal­A,­most­ studies­ show­globotriaosylceramide­
deposition in tissues and organs, leading to some func-
tional damage of the organ. Hence extra -renal symp-
toms are important and have prognostic impact, since 
renal transplantation does not correct the underlying 
metabolic defect in other organs.
Anecdotal studies have suggested that ERT therapy 
may have a beneficial effect in kidney transplant 
patients with Fabry disease. Mignani et al.25 assessed 
ERT treatment in three kidney transplant patients with 
Fabry and severe cardiac involvement. After 18 months, 
the extra -renal symptoms disappeared and renal func-
tion was preserved. In 2007, Pastores et al.26, in a phase 
II open -label trial, assessed the safety of agalsidase alfa 
(0.2 mg/kg every other week) in a population of 9 dialy-
sis patients, 13 kidney transplant patients, and 22 non-
-ESRD patients with Fabry disease, over a median 
follow -up period of 42 weeks (the study was stopped 
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early by the sponsor when ERT became commercially 
available). The authors concluded that agalsidase alfa 
administration was safe in this population.
Mignani et al. in a registry -based cohort of AFd 
patients on renal replacement therapy receiving ERT, 
assessed left ventricular mass index (LVMI) and renal 
allograft function at baseline and at yearly intervals 
thereafter.27. Thirty -four patients were included (17 
had renal transplantation and 17 under dialysis). The 
mean ERT duration for dialysis and transplant patients 
was 45.1 and 48.4 months, respectively. The analysis 
after four years of ERT showed that LVMI increased in 
dialysis patients and had no change in transplant 
patients. Over the follow -up period, transplant patients 
showed stable renal function and an increase in pro-
teinuria from 92 mg/day (baseline) to 180 mg/day. 
Cibulla et al.9 evaluated all European patients in the 
Fabry Outcome Survey with a history of kidney trans-
plantation. Thirty -six of 837 patients had a history of 
kidney transplantation and were included in the study. 
Of these, twenty patients received ERT with agalsidase 
alfa (at a standard dose of 0.2 mg/kg every other week) 
for a median duration of treatment of 3.5 years. During 
2 years of ERT, renal function decreased slightly (eGFR 
59.2 ml/min/1.73 m2 at baseline and 51.1 ml/min/1.73 
m2 at 2 years) and proteinuria remained stable. There 
were no reports of interactions between ERT and other 
medications, particularly immunosuppressive agents10.
As time goes by, damage to vital organ systems pro-
gresses leading to cardiovascular and cerebrovascular 
complications that limit life -expectancy1.
Fabry cardiomyopathy is related to the storage of 
globotriaosylceramides in myocytes28 with subsequent 
concentric hypertrophy and myocardium remodelling, 
resulting in irreversible fibrosis, conduction abnormali-
ties, valvulopathy and myocardial infarction29. Recently 
a retrospective uncontrolled study was published ana-
lysing the effectiveness of agalsidase alfa enzyme 
replacement on Fabry -associated cardiomyopathy, 
evaluating the outcomes after approximately 10 years 
of treatment30. Forty -five adult patients were included 
and the authors reported heart failure improvement 
by at least one class in 22/42 patients, and angina scores 
were stable or improved in 41/42 patients. Of note, 
this type of analysis, presenting the proportion of 
patients with/without a beneficial effect of the inter-
vention, instead of analysing the whole group, has a 
high risk of bias. No patient with left ventricular hyper-
trophy (LVH) at treatment initiation showed a decline 
in left ventricular mass. The authors concluded that 10 
years of agalsidase alfa treatment appeared to have 
beneficial effects for controlling progression and 
improving some symptoms of Fabry -associated 
cardiomyopathy.
Cerebrovascular involvement can lead to a wide 
variety of symptoms such as dizziness, transient isch-
aemic attacks, ischaemic strokes, vascular dementia 
and constitute a major burden in both untreated and 
treated patients31. The prevalence of strokes in AFd is 
about 6.9% in males and 4.3% in females, much higher 
than in the general population1. The majority of strokes 
are due to microvascular disease and brain imaging 
can be used to diagnose white matter lesions before 
they manifest clinically31. Data on agalsidase alfa ther-
apy reducing or preventing the cerebrovascular com-
plications associated with AFd is scarce1. Fellgiebel et 
al. reported recently the first evidence of clinically 
significant stabilisation of, or reduction in, white matter 
lesions in patients treated with agalsidase -beta ERT31. 
The authors analysed 41 AFd patients (25 on ERT, 16 
on placebo) over 27 months of follow -up (12 -33 
months) and concluded that burden in patients on ERT 
was more likely to remain stable, compared with 
patients on placebo. These data had more power if ETR 
was started at younger ages.
We report a successful case of 19 years’ kidney trans-
plant in which the last 10 were under ERT and with no 
major adverse events reported. We emphasise the fact 
that at the beginning of ERT the patient had already 
advanced disease and established organ injury, such 
as ocular, pulmonary, cerebrovascular, cardiac and 
renal, and organ injury remained stable under agalsi-
dase beta (Fabrazyme®) given intravenously every two 
weeks at a dose of 1 mg/kg body weight.
 CONCLUSION
In the case reported we highlight the importance of 
awareness of this rare disease, since the diagnosis is 
sometimes delayed for many years. This is especially 
true among high -risk groups with cardiomyopathy, 
juvenile strokes and chronic kidney disease, including 
those on dialysis or those who have undergone a kidney 
transplant. Early recognition of the disease is important 
to prevent the late life -threatening cardiac and cere-
brovascular manifestations.
Kidney transplantation is recommended for AFd 
patients suffering from end -stage renal disease. Current 
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experience with renal transplantation in AFd patients 
also indicates that ERT is a safe and effective treatment 
for extra -renal Fabry manifestations and one that slows 
disease progression, although randomized controlled 
studies with longer follow -up are needed.
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